摘要
观察艾塞那肽对2型糖尿病患者血糖控制情况。将2010年7月～12月间应用艾塞那肽的15例2型糖尿病患者进行一般资料分析:包括年龄、糖尿病病程、空腹血糖、餐后血糖、糖化血红蛋白,甘油三酯、胆固醇、就诊时降糖药物应用药统计。对患者进行艾塞那肽5μg一日2次早晚餐前1 h皮下注射后,观察用药前后空腹血糖及餐后2 h血糖变化。结果显示用艾塞那肽后空腹血糖及餐后血糖均较用药前下降,艾塞那肽降低餐后血糖较空腹血糖程度高。艾塞那肽可短时间内有效降低空腹及餐后血糖,降低餐后血糖较空腹血糖效果好。
The purpose is to observe the control of blood glucose fevel in type Ⅱ diabetic patients using Exenatide-4.15 type Ⅱ diabetic patients using Exenatide-4 were chosen from July to December in 2010.The clinical data such as age,the course of the diabetes,fasting glucose,postprandial glucose,glycated hemoglobin,triglycerides,cholesterol,and the treatment method before they used Exenatide-4 were all analysed.Patients were injected Exenatide-4 5μg twice a day one hour before breakfast and dinner,then was observed the change of FPG and two-hour PBG after one week.The results showed that both FPG and PBG all descended after using Exenatide-4,the degressive level of PBG was greater than the FPG.It can be concluded that Exenatide-4 can reduce both FPG and PBG in a short time,and the reduction of PBG is greater than that of FPG.
出处
《药物生物技术》
CAS
CSCD
2012年第1期62-64,共3页
Pharmaceutical Biotechnology
关键词
艾塞那肽
2型糖尿病
空腹血糖
餐后2H血糖
Exenatide-4
TypeⅡ Diabetes
Fasting blood glucose（FBG）
Two-hour postprandial blood glucose（PBG）
